
  
    
      
        Background_NNP &_CC Aims_VBZ
        MAdCAM-_NNP 1_CD is_VBZ a_DT 60_CD kD_NN endothelial_NN cell_NN adhesion_NN molecule_NN
        expressed_VBD on_IN the_DT surface_NN of_IN high_JJ endothelial_NN venules_NNS in_IN the_DT
        gut_NN ,_, and_CC in_IN Peyers_NNP patches_NNS ._. MAdCAM-_NNP 1_CD is_VBZ expressed_VBN basally_RB
        in_IN these_DT tissues_NNS and_CC is_VBZ dramatically_RB increased_VBN in_IN
        inflammatory_JJ bowel_NN disease_NN (_( IBD_NNP )_) ._. In_IN IBD_NNP ,_, especially_RB
        Crohn_NNP 's_POS disease_NN ,_, MAdCAM-_NNP 1_CD acts_NNS as_IN the_DT main_JJ ligand_NN for_IN
        a_DT 4_CD b_SYM 7_CD -_: expressing_VBG lymphocytes_NNS and_CC recruits_VBZ these_DT lymphocytes_NNS
        into_IN the_DT intestine_NN where_WRB they_PRP initiate_VBP and_CC sustain_VB chronic_JJ
        inflammation_NN ._. Several_JJ animal_NN models_NNS and_CC human_JJ studies_NNS
        support_VBP an_DT absolute_JJ requirement_NN for_IN both_DT MAdCAM-_NNP 1_CD and_CC a_DT 4_CD b_SYM 7_CD
        in_IN the_DT production_NN of_IN immune_JJ models_NNS of_IN colitis_NNS ._. MAdCAM-_NNP 1_CD is_VBZ
        expressed_VBN on_IN the_DT surface_NN of_IN lymphoid_NN endothelial_NN cells_NNS in_IN
        response_NN to_TO several_JJ cytokines_NNS including_VBG TNF-α_NNP and_CC IL-lb_NNP ,_,
        however_RB ,_, the_DT signal_NN transduction_NN pathways_NNS involved_VBN in_IN
        MAdCAM-_NNP 1_CD are_VBP still_RB not_RB well_RB understood_VBN ._. However_RB ,_, since_IN
        MAdCAM-_NNP 1_CD is_VBZ induced_VBN by_IN Th_NNP 1_CD cytokines_NNS ,_, like_IN TNF-α_NNP and_CC IL-_NNP 1_CD b_SYM ,_,
        it_PRP is_VBZ likely_JJ that_IN its_PRP$ induction_NN is_VBZ mechanistically_RB similar_JJ
        to_TO that_DT of_IN adhesion_NN molecules_NNS like_IN ICAM-_NNP 1_CD and_CC VCAM-_NNP 1_CD ._. These_DT
        adhesion_NN molecules_NNS are_VBP also_RB induced_VBN by_IN Th_NNP 1_CD cytokines_NNS and_CC
        require_VB activation_NN of_IN the_DT NF-kB_NNP /_NN PARP_NNP ._. The_DT activation_NN of_IN
        these_DT transcription_NN factors_NNS also_RB requires_VBZ the_DT formation_NN of_IN
        intracellular_NN oxidants_NNS ,_, since_IN mobilization_NN of_IN these_DT
        adhesion_NN molecules_NNS in_IN response_NN to_TO cytokines_NNS can_MD be_VB
        prevented_VBN by_IN antioxidants_NNS like_IN PDTC_NNP or_CC NAC_NNP ._.
        Physiologically_NNP ,_, the_DT expression_NN of_IN these_DT cell_NN adhesion_NN
        molecules_NNS also_RB appears_VBZ to_TO be_VB limited_VBN by_IN the_DT formation_NN of_IN NO_DT
        through_IN either_DT constituitive_JJ ,_, or_CC inducible_JJ forms_NNS of_IN nitric_JJ
        oxide_NN synthase_NN (_( eNOS_NN ,_, iNOS_NN )_) ._. It_PRP has_VBZ been_VBN suggested_VBN that_IN NO_DT
        could_MD inhibit_VB the_DT transcription_NN /_NN translation_NN of_IN adhesion_NN
        molecules_NNS through_IN either_DT scavenging_VBG of_IN signal_NN oxidants_NNS
        produced_VBN in_IN response_NN to_TO cytokines_NNS ,_, or_CC through_IN covalent_NN
        modification_NN of_IN polypeptides_NNS in_IN the_DT signaling_VBG pathway_NN ,_, like_IN
        IkB_NNP ._.
        Here_RB ,_, we_PRP examine_VBP the_DT induction_NN of_IN MAdCAM-_NNP 1_CD by_IN TNF-α_NNP ,_, and_CC
        evaluated_VBD whether_IN endogenous_JJ nitric_JJ oxide_NN (_( from_IN eNOS_NN and_CC
        iNOS_NN )_) ,_, or_CC exogenous_JJ NO_DT (_( from_IN rapid_JJ or_CC slow-releasing_JJ NO_DT
        donors_NNS )_) affect_VB the_DT expression_NN of_IN MadCAM-_NNP 1_CD ._. Our_PRP$ data_NNS suggest_VBP
        that_IN in_IN this_DT model_NN ,_, endogenous_JJ NO_DT (_( derived_VBN from_IN either_DT iNOS_NN
        or_CC eNOS_NN )_) ,_, does_VBZ not_RB significantly_RB influence_VB MAdCAM-_NNP 1_CD
        expression_NN ,_, however_RB ,_, both_DT rapid_JJ and_CC slow_JJ releasing_VBG NO_DT
        donors_NNS can_MD potently_RB inhibit_VB the_DT expression_NN of_IN MAdCAM-_NNP 1_CD and_CC
        reduce_VB lymphocyte_NN endothelial_NN adhesion_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Reagents_NNP
          Recombinant_NNP mouse_NN TNF-α_NNP was_VBD purchased_VBN from_IN ENDOGEN_NNP
          (_( Stoughton_NNP ,_, MA_NNP )_) ._. DETA-NO_NNP ,_, SperNO_NNP and_CC 1400_CD w_NN were_VBD
          purchased_VBN from_IN Alexis_NNP corp_NN ._. (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. L-NAME_NNP was_VBD
          purchased_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._.
        
        
          Cell_NNP culture_NN
          SVEC_NNP 4_CD -_: 10_CD is_VBZ an_DT endothelial_NN cell_NN line_NN derived_VBN by_IN SV_NNP 40_CD
          (_( strain_NN 4_CD A_DT )_) transformation_NN of_IN murine_NN small_JJ vascular_NN
          endothelial_NN cells_NNS originally_RB isolated_VBN from_IN axillary_JJ lymph_NN
          node_NN vessels_NNS of_IN an_DT adult_NN male_JJ C_NNP 3_CD H_NNP /_NN Hej_NNP mouse_NN [_NN 1_CD ]_NN ._. These_DT
          cell_NN types_NNS were_VBD all_DT maintained_VBN in_IN DMEM_NNP with_IN 10_CD %_NN fetal_JJ
          calf_NN serum_NN with_IN 1_CD %_NN antibiotic_JJ /_NN antimycotic_JJ ,_, and_CC seeded_VBN
          onto_IN 24_CD -_: well_RB tissue_NN culture_NN plates_NNS at_IN approximately_RB
          20_CD ,_, 000_CD cells_NNS /_NN cm_NN 2_CD ;_: cultures_NNS were_VBD used_VBN immediately_RB after_IN
          reaching_VBG confluency_NN ._.
        
        
          Lymphocytes_NNP
          Mouse_NNP CD_NNP 8_CD +_NN T_NN cell_NN lymphoma_NN TK-_NNP 1_CD cells_NNS which_WDT
          constituitively_RB express_VB α_NN 4_CD β_NN 7_CD were_VBD obtained_VBN from_IN Dr_NNP ._.
          Eugene_NNP Butcher_NNP (_( Stanford_NNP University_NNP )_) ._. These_DT cells_NNS were_VBD
          cultured_JJ in_IN RPMI_NNP medium_NN supplemented_JJ with_IN 10_CD %_NN FCS_NNP ,_, 2_CD mM_NN
          L-_NNP glutamine_NN ,_, and_CC 0_CD ._. 05_CD mM_NN 2_CD -_: mercaptoethanol_NN without_IN
          antibiotic_JJ /_NN antimycotic_JJ ._.
        
        
          RT-PCR_NNP analysis_NN
          MAdCAM-_NNP 1_CD message_NN in_IN response_NN to_TO TNF-α_NNP and_CC blockers_NNS was_VBD
          measured_VBN by_IN RT-PCR_NNP ._. When_WRB NO_DT donors_NNS were_VBD used_VBN they_PRP were_VBD
          given_VBN as_IN co-treatments_JJ ,_, NO_DT synthase_NN blockers_NNS (_( L-NAME_NNP )_)
          were_VBD pre-treated_JJ for_IN 60_CD minutes_NNS prior_RB to_TO incubation_NN ._.
          Total_JJ cell_NN RNA_NNP was_VBD extracted_VBN from_IN SVEC_NNP cells_NNS using_VBG the_DT
          RNeasy_NNP Kit_NNP (_( QIAGEN_NNP Inc_NNP ._. ,_, Valencia_NNP ,_, CA_NNP )_) according_VBG to_TO
          manufacturers_NNS instructions_NNS ._. First-strand_NNP cDNAs_NNS were_VBD
          prepared_VBN from_IN 6_CD μg_NN of_IN total_JJ RNA_NNP using_VBG a_DT mixture_NN of_IN
          oligo_NN (_( dT_NN )_) 
          12_CD -_: 18_CD and_CC random_JJ hexamer_NN primers_NNS with_IN
          Superscript_NNP reverse_VB transcriptase_NN (_( Promega_NNP ,_, Madison_NNP ,_, WI_NNP )_) ._.
          The_DT following_VBG oligonucleotides_NNS were_VBD synthesized_JJ and_CC used_VBN
          as_IN primers_NNS :_: PI_NNP ;_: 5_CD '_POS -_: CCTAGTACCCTACCAGCTCA-_NNP 3_CD '_POS P_NN 2_CD ;_:
          5_CD '_POS -_: ATCTCCTCTTCTTGCTCTGG-_NNP 3_CD '_POS (_( P_NN 1_CD -_: P_NN 2_CD ;_: 474_CD bp_NN )_)
          As_IN controls_NNS ,_, a_DT 307_CD bp_NN (_( sense_NN ;_:
          5_CD '_POS -_: CGGTGTGAACGGATTTGGCCGTAT-_NNP 3_CD '_POS ,_, antisense_NN ;_:
          5_CD '_POS -_: GGCCTTCTCCATGGTGGTGAAGAC-_NNP 3_CD '_POS )_) fragment_NN of_IN murine_NN GAPDH_NNP
          was_VBD also_RB amplified_VBN in_IN a_DT same_JJ tube_NN with_IN primers_NNS 1_CD and_CC 2_CD ._.
          Primer_NNP sequences_NNS for_IN GAPDH_NNP were_VBD separated_VBN by_IN introns_NNS to_TO
          control_VB for_IN potential_JJ sample_NN contamination_NN by_IN genomic_JJ
          DNA_NNP ._. PCR_NNP amplification_NN was_VBD performed_VBN at_IN 95_CD °_NN C_NNP for_IN 3_CD min_NN ;_:
          followed_VBN by_IN 30_CD cycles_NNS of_IN 94_CD °_NN C_NNP for_IN 1_CD min_NN ,_, 55_CD °_NN C_NNP for_IN 1_CD min_NN
          and_CC 72_CD °_NN C_NNP for_IN 1_CD min_NN ,_, and_CC then_RB at_IN 72_CD °_NN C_NNP for_IN the_DT final_JJ 5_CD min_NN ._.
          The_DT PCR_NNP products_NNS were_VBD separated_JJ on_IN 1_CD ._. 2_CD %_NN agarose_NN gels_NNS ._. To_TO
          normalize_VB mRNA_NN levels_NNS ,_, the_DT density_NN of_IN the_DT MAdCAM-_NNP 1_CD and_CC
          GAPDH_NNP bands_NNS from_IN the_DT same_JJ lane_NN were_VBD measured_VBN by_IN scanning_VBG
          the_DT three_CD replicate_VB gels_NNS (_( n_NN =_SYM 3_LS )_) ,_, using_VBG a_DT HP_NNP ScanJet_NNP ™_NN
          flatbed_JJ scanner_NN ._. Images_NNP were_VBD analyzed_VBN for_IN density_NN using_VBG
          Image_NN Pro_FW Plus_NNP ™_NN image_NN analysis_NN software_NN (_( Media_NNP
          Cybernetics_NNP ,_, Silver_NNP Springs_NNP ,_, MD_NNP )_) ._. The_DT data_NNS are_VBP calculated_VBN
          as_IN the_DT rations_NNS of_IN the_DT optical_JJ density_NN values_NNS to_TO those_DT of_IN
          GAPDH_NNP ,_, and_CC are_VBP presented_VBN as_IN a_DT persentage_NN of_IN TNF-α_NNP
          stimulated_VBN density_NN ration_NN ._. Significant_JJ changes_NNS in_IN
          MAdCAM-_NNP 1_CD densities_NNS were_VBD determined_VBN using_VBG the_DT Instat_NNP ™_NN
          statistical_JJ package_NN (_( Graphpad_NNP Software_NNP ,_, San_NNP Diego_NNP ,_,
          CA_NNP )_) ._.
        
        
          Western_JJ analysis_NN of_IN cell_NN lysates_NNS
          Monolayers_NNP were_VBD pretreated_JJ (_( NO_DT synthase_NN blockers_NNS )_) or_CC
          co-treated_JJ (_( NO_DT donors_NNS )_) with_IN cytokines_NNS and_CC harvested_VBN at_IN 24_CD
          hours_NNS ._. Equal_NNP quantities_NNS of_IN protein_NN (_( 75_CD μg_NN )_) from_IN each_DT
          sample_NN were_VBD electrophoretically_RB separated_JJ on_IN 7_CD ._. 5_CD %_NN
          SDS-PAGE_NNP gels_NNS ._. Gels_NNP were_VBD transferred_VBN to_TO nitrocellulose_NN
          membranes_NNS (_( Sigma_NNP )_) and_CC blocked_VBN with_IN 5_CD %_NN milk_NN powder_NN in_IN PBS_NNP
          at_IN 4_CD °_NN C_NNP (_( overnight_JJ )_) ._. These_DT membranes_NNS were_VBD washed_VBN twice_RB for_IN
          10_CD min_NN with_IN wash_NN buffer_NN (_( 0_CD ._. 1_LS %_NN milk_NN powder_NN in_IN PBS_NNP )_) ._.
          Primary_JJ rat_NN anti-mouse_JJ MadCAM-_NNP 1_CD mAb_NN (_( MECA_NNP 367_CD ,_,
          Pharmingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) [_NN 2_CD ]_NN was_VBD added_VBN at_IN a_DT
          concentration_NN of_IN 10_CD μg_NN /_NN ml_NN and_CC incubated_JJ at_IN room_NN
          temperature_NN for_IN 2_CD h_NN ._. These_DT membranes_NNS were_VBD washed_VBN twice_RB
          with_IN wash_NN buffer_NN ._. Secondary_JJ goat_NN anti-rat_JJ horseradish_NN
          peroxidase_NN conjugated_JJ secondary_JJ antibody_NN (_( Sigma_NNP )_) was_VBD
          added_VBN at_IN a_DT 1_CD :_: 2000_CD dilution_NN for_IN 2_CD h_NN ._. Lastly_NNP ,_, membranes_NNS
          were_VBD washed_VBN 3_CD times_NNS and_CC developed_VBN using_VBG the_DT enhanced_JJ
          chemiluminescence_NN (_( ECL_NNP )_) detection_NN system_NN (_( Amersham_NNP ,_, La_NNP
          Jolla_NNP ,_, CA_NNP )_) ._. The_DT density_NN of_IN MAdCAM-_NNP 1_CD staining_VBG was_VBD measured_VBN
          by_IN scanning_VBG the_DT 60_CD kD_NN band_NN ,_, using_VBG a_DT HP_NNP ScanJet_NNP ™_NN flatbed_JJ
          scanner_NN ._. Images_NNP were_VBD analyzed_VBN for_IN density_NN using_VBG Image_NN Pro_FW
          Plus_NNP ™_NN image_NN analysis_NN software_NN (_( Media_NNP Cybernetics_NNP )_) ._. The_DT
          data_NNS are_VBP expressed_VBN as_IN a_DT percentage_NN of_IN TNF-α-induced_NNP level_NN
          of_IN density_NN ._. Significant_JJ changes_NNS in_IN MAdCAM-_NNP 1_CD densities_NNS
          were_VBD determined_VBN using_VBG the_DT Instat_NNP ™_NN statistical_JJ package_NN
          (_( Graphpad_NNP Software_NNP )_) ._. For_IN NF-κB_NNP p_NN 65_CD blotting_VBG ,_, rabbit_NN
          anti-p_JJ 65_CD polyclonal_NN (_( Rockland_NNP ,_, Germany_NNP )_) and_CC goat_NN
          anti-rabbit_JJ horseradish_NN peroxidase_NN conjugated_JJ antibody_NN
          (_( Sigma_NNP )_) were_VBD used_VBN as_IN primary_JJ and_CC secondary_JJ antibody_NN
          respectively_RB at_IN a_DT 1_CD :_: 1000_CD dilution_NN ._. For_IN giving_VBG experiment_NN ,_,
          each_DT treatment_NN was_VBD performed_VBN at_IN least_JJS in_IN triplicate_NN ._.
        
        
          p_NN 65_CD immunoblotting_VBG
          For_IN NF-κB_NNP p_NN 65_CD blotting_VBG ,_, SVEC_NNP were_VBD pretreated_JJ for_IN 1_CD h_NN
          with_IN or_CC without_IN inhibitors_NNS ,_, and_CC then_RB incubated_JJ for_IN 1_CD h_NN
          with_IN either_DT vehicle_NN or_CC TNF-α_NNP (_( 20_CD ng_NN /_NN ml_NN )_) ._. Nuclear_JJ extracts_NNS
          were_VBD prepared_VBN as_IN described_VBN previously_RB [_NN 3_CD ]_NN ._. rabbit_NN
          anti-p_JJ 65_CD polyclonal_NN (_( Rockland_NNP ,_, Germany_NNP )_) and_CC goat_NN
          anti-rabbit_JJ horseradish_NN peroxidase_NN conjugated_JJ antibody_NN
          (_( Sigma_NNP )_) were_VBD used_VBN as_IN primary_JJ and_CC secondary_JJ antibody_NN
          respectively_RB at_IN a_DT 1_CD :_: 1000_CD dilution_NN ._. For_IN giving_VBG experiment_NN ,_,
          each_DT treatment_NN was_VBD performed_VBN at_IN least_JJS in_IN triplicate_NN ._.
        
        
          TK-_NNP 1_CD lymphocyte_NN adhesion_NN assay_NN
          Lymphocyte_NNP adhesion_NN assays_NNS were_VBD performed_VBN as_RB
          previously_RB described_VBD [_NN 4_CD ]_NN with_IN modifications_NNS ._. Briefly_NNP ,_,
          TK-_NNP 1_CD cells_NNS were_VBD suspended_VBN in_IN Hank_NNP 's_POS Balanced_NNP salt_NN
          solution_NN (_( HBSS_NNP )_) and_CC radiolabeled_JJ by_IN incubating_VBG TK-_NNP 1_CD cells_NNS
          at_IN 2_CD ×_NN 10_CD 7_CD cells_NNS /_NN ml_NN with_IN 30_CD μCi_NN Na_NNP 51_CD CrO_NNP 
          4_CD /_NN ml_NN (_( New_NNP England_NNP Nuclear_NNP ,_, Natick_NNP ,_,
          MA_NNP )_) at_IN 37_CD °_NN C_NNP for_IN 60_CD min_NN ._. The_DT cells_NNS were_VBD then_RB washed_VBN twice_RB
          with_IN ice-cold_JJ HBSS_NNP ,_, spun_VBN at_IN 250_CD g_SYM for_IN 8_CD min_NN to_TO remove_VB
          unincorporated_JJ radioactivity_NN and_CC resuspended_JJ in_IN HBSS_NNP ._. The_DT
          TK-_NNP 1_CD lymphocyte_NN cell_NN line_NN used_VBN in_IN this_DT assay_NN expresses_VBZ
          high_JJ levels_NNS of_IN the_DT alpha_NN 4_CD beta_NN 7_CD integrin_NN ,_, which_WDT can_MD
          interact_NN with_IN multiple_JJ ligands_NNS including_VBG mucosal_NN
          addressin-_NN 1_CD (_( MAdCAM-_NNP 1_LS )_) ,_, as_RB well_RB as_IN VCAM-_NNP 1_CD ,_, L-_NNP selectin_NN and_CC
          fibronectin_NN [_NN 5_CD ]_NN ._. To_TO activate_VBP endothelium_NN ,_, the_DT monolayers_NNS
          were_VBD incubated_JJ with_IN TNF-α_NNP (_( 20_CD ng_NN /_NN ml_NN )_) for_IN 24_CD h_NN as_IN
          described_VBN ._. Cytokine-treated_NNP endothelial_NN cells_NNS were_VBD washed_VBN
          three_CD times_NNS with_IN media_NNS ._. Labeled_NNP TK-_NNP 1_CD cells_NNS were_VBD then_RB
          added_VBN to_TO the_DT endothelium_NN at_IN a_DT 5_CD :_: 1_CD lymphocyte_NN :_: endothelial_NN
          cell_NN ratio_NN [_NN 6_CD ]_NN and_CC allowed_VBN to_TO bind_NN for_IN 30_CD min_NN under_IN
          static_JJ conditions_NNS ._. At_IN the_DT end_NN of_IN the_DT incubation_NN period_NN ,_,
          the_DT supernatant_NN was_VBD removed_VBN and_CC the_DT monolayers_NNS were_VBD
          washed_VBN twice_RB with_IN HBSS_NNP ._. The_DT remaining_VBG endothelial_NN cells_NNS
          and_CC adherent_NN TK-_NNP 1_CD cells_NNS were_VBD solubilized_JJ with_IN IN_IN NaOH_NNP ._.
          The_DT 51_CD Cr_NNP activity_NN of_IN the_DT supernatant_NN ,_, washed_VBD fluid_JJ ,_, and_CC
          lysate_NN were_VBD assessed_VBN in_IN a_DT gamma_NN counter_NN ._. The_DT percent_NN of_IN
          added_VBD TK-_NNP 1_CD cells_NNS that_WDT adhered_VBD to_TO the_DT SVEC_NNP monolayers_NNS was_VBD
          quantified_VBN as_IN follows_VBZ :_: %_NN adhesion_NN =_SYM [_NN cpm_NN in_IN lysate_NN /_NN (_( cpm_NN
          in_IN lysate_NN +_NN cpm_NN in_IN supernatant_NN and_CC wash_VB )_) ]_NN ×_NN 100_CD ._. the_DT
          average_NN of_IN four_CD identically_RB treated_VBN monolayers_NNS ._.
        
        
          Statistical_NNP Analysis_NNP
          All_DT values_NNS are_VBP expressed_VBN as_IN mean_NN ±_NN SE_NNP ._. Data_NNP were_VBD
          analyzed_VBN using_VBG one-way_JJ ANOVA_NNP with_IN Bonferroni_NNP 's_POS correction_NN
          for_IN multiple_JJ comparisons_NNS ._. Significance_NN was_VBD accepted_VBN at_IN p_NN
          <_NN 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Effect_NN of_IN NO_DT on_IN MAdCAM-_NNP 1_CD in_IN SVEC_NNP
          We_PRP investigated_VBD the_DT effect_NN of_IN DETA-NONOate_NNP on_IN
          TNF-α-induced_NNP MAdCAM-_NNP 1_CD message_NN in_IN SVEC_NNP by_IN RT-PCR_NNP ._. Figure_NN
          1_CD shows_VBZ the_DT PCR_NNP products_NNS obtained_VBN with_IN the_DT promers_NNS ,_, which_WDT
          amplify_VB the_DT first_JJ and_CC second_JJ IgG-like_NNP domain_NN of_IN MAdCAM-_NNP 1_CD
          [_NN 7_CD ]_NN ._. A_DT strong_JJ band_NN is_VBZ detected_VBN as_IN MAdCAM-_NNP 1_CD transcript_NN
          after_IN stimulated_VBN with_IN TNF-α_NNP (_( 20_CD ng_NN /_NN ml_NN )_) for_IN 12_CD h_NN ._.
          Pretreatment_NNP of_IN DETA-NONOate_NNP (_( 100_CD μM_NN )_) blocked_VBD the_DT TNF-α_NNP
          (_( 20_CD ng_NN /_NN ml_NN ,_, 12_CD h_NN )_) induced_VBN MAdCAM-_NNP 1_CD transcript_NN (_( 37_CD ._. 3_LS %_NN of_IN
          TNF-α_NNP treated_VBD )_) while_IN there_EX was_VBD no_DT equivalent_NN change_NN in_IN
          GAPDH_NNP (_( Figure_NN 1_LS )_) ._.
        
        
          TNF-α_NNP induces_VBZ MAdCAM-_NNP 1_CD protein_NN expression_NN which_WDT is_VBZ
          reduced_VBN by_IN NO_DT donors_NNS
          TNF-α_NNP (_( 20_CD ng_NN /_NN ml_NN )_) induced_VBN MAdCAM-_NNP 1_CD expression_NN is_VBZ
          blocked_VBN both_DT by_IN the_DT short-acting_JJ and_CC long-acting_JJ NO_DT
          donors_NNS ,_, SperNO_NNP and_CC DETA-NO_NNP respectively_RB ._. SperNO_NNP
          significantly_RB reduces_VBZ MAdCAM-_NNP 1_CD expression_NN at_IN 100_CD and_CC 1000_CD
          uM_NN (_( Fig_NNP ._. 2_LS )_) ,_, while_IN the_DT long_JJ acting_NN NO_DT donor_NN DETA-NO_NNP
          significantly_RB reduced_VBD MAdCAM-_NNP 1_CD at_IN a_DT only_RB 1_CD /_NN 10_CD the_DT
          concentration_NN of_IN SperNO_NNP needed_VBD to_TO reduce_VB MAdCAM-_NNP 1_CD
          expression_NN (_( 10_CD uM_NN and_CC 100_CD uM_NN significantly_RB attenuated_JJ
          MAdCAM-_NNP 1_CD expresssion_NN )_) ._.
        
        
          NO_DT donors_NNS block_VBP TNF-α_NNP induces_VBZ nuclear_JJ translocation_NN
          of_IN p_NN 65_CD
          Figure_NN 2_CD Cshows_NNP that_IN TNF-α_NNP (_( 20_CD ng_NN /_NN ml_NN )_) significantly_RB
          increased_VBN nuclear_JJ translocation_NN of_IN p_NN 65_CD ,_, a_DT subunit_NN of_IN the_DT
          p_NN 50_CD /_NN p_NN 65_CD NF-kB_NNP complex_NN ._. In_IN the_DT presence_NN of_IN DETA-NO_NNP (_( 100_CD
          uM_NN )_) or_CC SperNO_NNP (_( 100_CD uM_NN )_) ,_, p_NN 65_CD nuclear_JJ translocation_NN was_VBD
          significantly_RB blocked_VBN as_IN visualized_JJ by_IN its_PRP$ appearance_NN in_IN
          western_JJ blotting_VBG of_IN nuclear_JJ samples_NNS ._.
        
        
          NO_DT synthase_NN inhibitors_NNS do_VBP not_RB induce_VB or_CC enhance_VB
          TNF-α_NNP induced_VBD MAdCAM-_NNP 1_CD expression_NN
          TNF-α_NNP induced_VBD MAdCAM-_NNP 1_CD was_VBD not_RB affected_VBN by_IN either_DT a_DT
          non-selective_JJ NO_DT synthase_NN inhibitor_NN ,_, L-NAME_NNP (_( 1_CD mM_NN )_) or_CC by_IN
          a_DT relatively_RB selective_JJ iNOS_NN inhibitor_NN ,_, 1400_CD -_: ω_NN (_( 100_CD μM_NN )_)
          (_( Fig_NNP ._. 3_LS )_) ._.
        
        
          Adhesion_NNP of_IN a_DT 4_CD b_SYM 7_CD expressing_VBG lymphocytes_NNS to_TO MAdCAM-_NNP 1_CD
          expressing_VBG cells_NNS
          Having_VBG established_VBD a_DT role_NN of_IN NO_DT donors_NNS in_IN the_DT
          regulation_NN of_IN MAdCAM-_NNP 1_CD expression_NN by_IN endothelial_NN cells_NNS ,_,
          we_PRP examined_VBD effects_NNS of_IN NO_DT donors_NNS on_IN the_DT adhesion_NN of_IN a_DT 4_CD b_SYM 7_CD
          expressing_VBG mouse_NN lymphocyte_NN cell_NN line_NN TK-_NNP 1_CD to_TO
          TNF-α-treated_NNP endothelial_NN cultures_NNS ._. Figure_NN 4_CD showed_VBD that_DT
          control_NN adhesion_NN of_IN TK-_NNP 1_CD cells_NNS was_VBD 12_CD ._. 3_LS ±_NN 0_CD ._. 98_CD %_NN ;_: TNF-α_NNP
          induced_VBD maximal_NN adhesion_NN (_( 29_CD ._. 8_CD ±_NN 1_CD ._. 30_CD %_NN ,_, p_NN <_NN 0_CD ._. 001_CD vs_NNS ._.
          untreated_JJ control_NN )_) at_IN 24_CD h_NN ._. This_DT relatively_RB high_JJ level_NN of_IN
          adhesion_NN was_VBD inhibited_VBD by_IN pre-incubation_JJ of_IN endothelial_NN
          monolayers_NNS with_IN anti-_NN MAdCAM-_NNP 1_CD antibody_NN ._. MAdCAM-_NNP 1_CD antibody_NN
          reduced_VBD TK-_NNP 1_CD adhesion_NN to_TO 17_CD ._. 0_CD ±_NN 1_CD ._. 18_CD %_NN (_( p_NN <_NN 0_CD ._. 001_CD vs_NNS ._.
          TNF-α_NNP treatment_NN )_) ,_, showing_VBG that_IN most_JJS of_IN the_DT TNF-α_NNP induced_VBD
          lymphocyte_NN adhesion_NN in_IN this_DT model_NN was_VBD MAdCAM-_NNP 1_CD dependent_JJ ._.
          Similarly_RB ,_, treatment_NN of_IN endothelial_NN monolayers_NNS with_IN
          DETA-NONOate_NNP significantly_RB reduced_VBD adhesion_NN to_TO 19_CD ._. 6_CD ±_NN
          0_CD ._. 72_CD %_NN of_IN that_DT induced_VBN by_IN TNF-α_NNP alone_RB (_( p_NN <_NN 0_CD ._. 001_CD )_) ._.
          DETA-NONOate_NNP did_VBD not_RB affect_VB lymphocyte_NN adhesion_NN to_TO
          untreated_JJ endothelial_NN monolayers_NNS (_( 
          data_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        Human_NNP IBD_NNP is_VBZ characterized_VBN by_IN the_DT extravasation_NN of_IN
        leukocytes_NNS ,_, especially_RB lymphocytes_NNS ,_, into_IN the_DT gut_NN ,_, where_WRB
        these_DT cells_NNS induce_VB and_CC sustain_VB chronic_JJ intestinal_NN
        inflammation_NN ._. [_NN 8_CD ]_NN ._. Lymphocyte_NNP homing_VBG to_TO both_DT normal_JJ
        tissues_NNS ,_, and_CC to_TO sites_NNS of_IN inflammation_NN is_VBZ ,_, regulated_VBN in_IN
        part_NN ,_, by_IN differential_NN expression_NN of_IN cell_NN surface_NN homing_VBG
        receptors_NNS ,_, and_CC their_PRP$ bonds_NNS with_IN tissue_NN specific_JJ vascular_NN
        addressins_NNS that_WDT are_VBP sites_NNS of_IN lymphocyte_NN recruitment_NN from_IN
        blood_NN [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Lymphocyte_NNP homing_VBG to_TO mucosal_NN lymphoid_NN
        tissues_NNS such_JJ as_IN Peyer_NNP 's_POS patches_NNS ,_, and_CC the_DT intestinal_NN lamina_NN
        propria_NN involves_VBZ a_DT single-chain_JJ 60_CD -_: Kd_NNP adhesion_NN
        glycoprotein_NN ,_, the_DT mucosal_NN vascular_NN addressin_NN MAdCAM-_NNP 1_CD [_NN 12_CD ,_,
        13_CD ]_NN ._.
        MAdCAM-_NNP 1_CD is_VBZ expressed_VBN on_IN endothelial_NN cells_NNS in_IN mesenteric_JJ
        lymph_NN nodes_NNS ,_, lamina_NN propria_NN of_IN the_DT small_JJ and_CC large_JJ
        intestine_NN ,_, and_CC the_DT lactating_VBG mammary_JJ gland_NN ._. Increased_VBN
        expression_NN of_IN MAdCAM-_NNP 1_CD on_IN murine_NN endothelial_NN cells_NNS can_MD be_VB
        induced_VBN after_IN stimulation_NN with_IN IL-_NNP 1_CD and_CC TNF-α_NNP ._. [_NN 13_CD ]_NN ._.
        MAdCAM-_NNP 1_CD has_VBZ also_RB been_VBN detected_VBN at_IN high_JJ levels_NNS on_IN colonic_JJ
        lamina_NN propria_NN venules_NNS from_IN mice_NNS with_IN hapten_NN induced_VBD
        colitis_NNS [_NN 14_CD ]_NN ,_, mice_NNS injected_VBN with_IN TNF-α_NNP [_NN 15_CD ]_NN ,_, or_CC colitic_JJ
        IL-_NNP 2_CD knockout_NN mice_NNS [_NN 16_CD ]_NN ._. The_DT interaction_NN of_IN the_DT α_NN 4_CD β_NN 7_CD
        integrin_NN on_IN a_DT subset_NN of_IN T_NN cells_NNS ,_, with_IN its_PRP$ ligand_NN ,_, MAdCAM-_NNP 1_CD ,_,
        on_IN high_JJ venular_NN and_CC lymphoid_NN endothelial_NN cells_NNS has_VBZ been_VBN
        shown_VBN to_TO be_VB support_NN the_DT entry_NN of_IN of_IN these_DT lymphocytes_NNS into_IN
        the_DT gut_NN in_IN IBD_NNP [_NN 8_CD ]_NN ._. However_RB ,_, this_DT process_NN is_VBZ still_RB not_RB
        well_RB understood_VBN ._.
        Immune-models_NNP of_IN colitis_NNS in_IN mice_NNS show_VBP that_IN the_DT
        MAdCAM-_NNP 1_CD /_NN B_NNP 7_CD integrin_NN bond_NN is_VBZ essential_JJ to_TO produce_VB colitis_NNS ._.
        CD_NNP 45_CD RB_NNP highCD_NN 4_CD +_NN T_NN lymphocytes_NNS (_( which_WDT normally_RB home_NN to_TO ,_, and_CC
        populate_VB the_DT colons_NNS of_IN severe-combined_JJ immune_JJ deficient_NN
        (_( '_POS SCID_NNP '_POS )_) mice_NNS )_) will_MD not_RB enter_VB the_DT gut_NN after_IN treatment_NN of_IN
        recipient_JJ animals_NNS with_IN either_DT MAdCAM-_NNP 1_CD ,_, or_CC α_NN 4_CD β_NN 7_CD specific_JJ
        antibody_NN ._. This_DT shows_VBZ that_IN this_DT pair_NN of_IN molecules_NNS is_VBZ clearly_RB
        involved_VBN in_IN cell_NN traffic_NN into_IN the_DT inflamed_JJ gut_NN [_NN 17_CD ]_NN ._.
        Therefore_RB ,_, it_PRP is_VBZ possible_JJ that_IN there_EX may_MD be_VB unregulated_JJ
        MAdCAM-_NNP 1_CD expression_NN in_IN IBD_NNP ,_, and_CC likely_JJ that_IN the_DT control_NN of_IN
        MAdCAM-_NNP 1_CD expression_NN may_MD be_VB an_DT effective_JJ potential_JJ treatment_NN
        for_IN IBD_NNP ._.
        With_IN respect_NN to_TO adhesion_NN ,_, adhesion_NN of_IN polymorphonuclear_NN
        leukocytes_NNS has_VBZ been_VBN shown_VBN to_TO be_VB enhanced_VBN by_IN treatment_NN with_IN
        NOS_NNP inhibitors_NNS ,_, similarly_RB Hokari_NNP et_CC al_NN ._. [_NN 18_CD ]_NN have_VBP also_RB
        demonstrated_VBN that_IN L-NAME_NNP promotes_VBZ the_DT adhesion_NN of_IN
        T-_NNP lymphocytes_NNS cells_NNS to_TO endothelium_NN in_IN vivo_NN ._.
        NO_DT is_VBZ an_DT important_JJ modulator_NN of_IN adhesion_NN molecule_NN
        expression_NN in_IN both_DT acute_JJ and_CC chronic_JJ inflammatory_JJ states_NNS ,_,
        and_CC may_MD influence_VB the_DT course_NN of_IN IBD_NNP ._. It_PRP is_VBZ known_VBN that_IN NO_DT
        can_MD function_VB both_DT as_IN an_DT oxidant_NN ,_, or_CC antioxidant_NN depending_VBG
        on_IN the_DT availability_NN of_IN reactive_JJ oxygen_NN species_NNS [_NN 19_CD ]_NN ._.
        Similarly_RB ,_, the_DT concentration_NN of_IN NO_DT can_MD also_RB augment_VB [_NN 20_CD ,_,
        21_CD ]_NN or_CC inhibit_VB [_NN 22_CD ,_, 23_CD ]_NN oxygen-radical_JJ mediated_JJ tissue_NN
        damage_NN and_CC lipid_NN peroxidation_NN ._. It_PRP has_VBZ also_RB been_VBN reported_VBN
        that_DT inhibition_NN of_IN endothelial_NN nitric_JJ oxide_NN synthases_NNS
        (_( using_VBG the_DT non-selective_JJ NOS_NNP inhibitor_NN L-NAME_NNP )_) ,_, induces_VBZ
        endothelial_NN adhesion_NN molecules_NNS (_( ICAM-_NNP 1_CD and_CC VCAM-_NNP 1_LS )_) in_IN HUVEC_NNP
        [_NN 24_CD ,_, 25_CD ]_NN ._.
        With_IN respect_NN to_TO NO_DT in_IN inflammatory_JJ bowel_NN disease_NN ._. Singer_NNP
        et_CC al_NN ._. ,_, [_NN 26_CD ]_NN found_VBD that_DT iNOS_NN expression_NN was_VBD significantly_RB
        increased_VBN in_IN colonic_JJ epithelia_NN from_IN individuals_NNS with_IN IBD_NNP ._.
        In_IN iNOS_NN deficient_NN mice_NNS ,_, McCafferty_NNP et_CC al_NN ._. (_( 1997_CD )_) [_NN 27_CD ]_NN
        reported_VBD that_IN acetic_JJ acid-induced_JJ colitis_NNS was_VBD more_RBR severe_JJ
        in_IN iNOS_NN -_: /_NN -_: deficient_NN animals_NNS ,_, consistent_JJ with_IN a_DT protective_JJ
        role_NN of_IN iNOS_NN derived_VBD NO_DT in_IN colitis_NNS ._.
        De_NNP Caterina_NNP et_CC al_NN ._. [_NN 28_CD ]_NN reported_VBD that_IN in_IN another_DT model_NN ,_,
        NO_DT blocked_VBD the_DT TNF-α_NNP or_CC IL-_NNP 1_CD β_NN induced_VBD expression_NN of_IN VCAM-_NNP 1_CD ,_,
        E-_NNP selectin_NN ,_, and_CC ICAM-_NNP 1_CD ._. Similarly_RB ,_, GSNO_NNP also_RB reduced_VBD NF-kB_NNP
        activation_NN (_( as_IN measured_VBN by_IN EMSA_NNP )_) ._. Further_RB ,_, Binion_NNP et_CC al_NN ._. [_NN
        29_CD ]_NN reported_VBD that_DT iNOS_NN expression_NN in_IN human_JJ intestinal_NN micro_JJ
        vascular_NN endothelial_NN cells_NNS inhibited_VBD leukocyte_NN adhesion_NN ,_,
        indicating_VBG that_DT iNOS_NN derived_VBD NO_DT may_MD control_VB inflammation_NN in_IN
        human_JJ IBD_NNP ._. Further_RB support_NN of_IN this_DT hypothesis_NNS comes_VBZ from_IN a_DT
        more_RBR recent_JJ report_NN by_IN Binion_NNP 's_POS group_NN showing_VBG that_IN
        individuals_NNS afflicted_VBN with_IN Crohn_NNP 's_POS colitis_NNS have_VBP an_DT apparent_JJ
        inability_NN to_TO express_VB iNOS_NN in_IN their_PRP$ intestinal_NN microvascular_NN
        endothelium_NN [_NN 29_CD ]_NN ._. McCafferty_NNP et_CC al_NN ._. ,_, [_NN 27_CD ,_, 30_CD ]_NN suggest_VBP
        that_IN in_IN IBD_NNP ,_, iNOS_NN blocks_NNS an_DT early_JJ ,_, obligatory_JJ phase_NN of_IN
        inflammation_NN ,_, but_CC perhaps_RB not_RB the_DT chronic_JJ phase_NN ._. Kubes_NNP and_CC
        McCafferty_NNP [_NN 31_CD ]_NN suggest_VBP in_IN IBD_NNP ,_, NO_DT may_MD be_VB either_CC
        beneficial_JJ or_CC detrimental_JJ and_CC may_MD reflect_VB the_DT tissue_NN source_NN
        (_( cell_NN type_NN )_) ,_, enzymatic_JJ source_NN of_IN NO_DT (_( eNOS_NN vs_NNS ._. iNOS_NN )_) and_CC
        rate_NN of_IN NO_DT production_NN ,_, as_RB well_RB as_IN the_DT bioavailability_NN of_IN
        oxidants_NNS in_IN these_DT different_JJ models_NNS ._.
        In_IN this_DT present_JJ study_NN ,_, we_PRP investigated_VBD how_WRB MAdCAM-_NNP 1_CD
        expression_NN in_IN cultured_JJ endothelial_NN cells_NNS is_VBZ altered_VBN by_IN NO_DT
        donors_NNS and_CC by_IN NO_DT synthase_NN inhibitors_NNS ._. We_PRP have_VBP also_RB examined_VBN
        how_WRB cytokines_NNS and_CC NO-modifying_NNP agents_NNS control_VBP adhesion_NN of_IN
        α_NN 4_CD β_NN 7_CD -_: expressing_VBG mouse_NN lymphocytes_NNS in_IN response_NN to_TO TNF-α_NNP ._.
        We_PRP observed_VBD that_IN both_DT a_DT short_JJ and_CC long-acting_JJ NO_DT donor_NN
        significantly_RB reduce_VB TNF-α-induced_NNP expression_NN of_IN MAdCAM-_NNP 1_CD
        expression_NN in_IN lymphatic_JJ endothelial_NN cells_NNS ._. The_DT effects_NNS of_IN
        NO_DT donors_NNS appear_VBP to_TO reflect_VB their_PRP$ ability_NN to_TO prevent_VB the_DT
        nuclear_JJ translocation_NN of_IN NF-kB_NNP ._. The_DT MAdCAM-_NNP 1_CD promoter_NN has_VBZ
        several_JJ NF-kB_NNP binding_JJ sites_NNS [_NN 32_CD ]_NN ,_, and_CC are_VBP necessary_JJ to_TO
        induce_VB MAdCAM-_NNP 1_CD expression_NN ._. Both_DT a_DT short_JJ and_CC long_JJ acting_NN NO_DT
        donor_NN blocked_VBD MAdCAM-_NNP 1_CD induction_NN ,_, but_CC the_DT slow-releasing_JJ NO_DT
        DETA-NO_NNP was_VBD apparently_RB at_IN least_JJS 10_CD times_NNS more_RBR effective_JJ
        than_IN SperNO_NNP (_( on_IN a_DT molar_NN basis_NN )_) ._. This_DT probably_RB reflects_VBZ the_DT
        need_NN for_IN persistently_RB elevated_VBD NO_DT to_TO block_NN cytokine_NN
        signaling_VBG in_IN this_DT system_NN ._.
        In_IN this_DT model_NN ,_, the_DT mechanism_NN through_IN which_WDT NO_DT donors_NNS
        limit_VBP inflammation_NN is_VBZ by_IN NF-kB_NNP inhibition_NN ,_, since_IN these_DT NO_DT
        donors_NNS effectively_RB block_VBP p_NN 65_CD translocation_NN into_IN the_DT
        nucleus_NN ._. Khan_NNP et_CC al_NN ._. [_NN 33_CD ]_NN demonstrated_VBN that_IN NO_DT donors_NNS
        blocked_VBD TNF-α_NNP induced_VBD NF-κB_NNP activation_NN in_IN human_JJ umbilical_JJ
        vein_NN endothelial_NN cells_NNS as_IN measured_VBN by_IN EMSA_NNP ._. Similarly_RB ,_,
        Spiecker_NNP [_NN 34_CD ]_NN showed_VBD that_IN GSNO_NNP ,_, blocked_VBD TNF-α_NNP induced_VBD
        NF-κB_NNP activation_NN by_IN EMSA_NNP in_IN human_JJ saphenous_JJ vein_NN
        endothelium_NN ._. However_RB in_IN that_DT model_NN IκBα_NNP ,_, the_DT inhibitor_NN of_IN
        the_DT NF-kB_NNP complex_NN was_VBD still_RB degraded_JJ ._. Therefore_RB ,_, NO_DT might_MD
        limit_VB NF-kB_NNP activation_NN through_IN pathways_NNS independent_JJ of_IN
        IkB-a_NNP ._. In_IN that_DT report_NN ,_, NO_DT was_VBD found_VBN to_TO induce_VB IκB_NNP synthesis_NN
        through_IN activation_NN of_IN its_PRP$ promoter_NN ,_, therefore_RB ,_, increased_VBD
        IkB-a_NNP might_MD also_RB contribute_VB to_TO NF-kB_NNP inhibition_NN ._. Several_JJ
        other_JJ possible_JJ pathways_NNS ,_, e_SYM ._. g_SYM ._. p_NN 38_CD ,_, p_NN 42_CD /_NN 44_CD MAPK_NNP and_CC
        transcription_NN factors_NNS ,_, e_SYM ._. g_SYM ._. SP_NNP 1_CD and_CC possibly_RB AP_NNP 2_CD ,_, Adh_NNP 1_CD
        (_( ETF_NNP )_) ,_, PEA_NNP 3_CD sites_NNS [_NN 32_CD ]_NN which_WDT could_MD also_RB contribute_VB to_TO
        NF-kB_NNP dependent_JJ gene_NN activation_NN and_CC might_MD participate_VB in_IN NO_DT
        mediated_JJ MAdCAM-_NNP 1_CD regulation_NN by_IN cytokines_NNS ._. [_NN 35_CD ]_NN have_VBP
        reported_VBN that_IN an_DT NO-releasing_NNP derivative_NN of_IN mesalamine_NN ,_,
        (_( one_CD agent_NN currently_RB used_VBD to_TO treat_VB gut_NN inflammation_NN )_) ,_,
        exhibits_VBZ enhanced_VBN anti-inflammatory_JJ effects_NNS compared_VBN to_TO the_DT
        parent_NN compound_NN ._. While_IN NO_DT donors_NNS are_VBP not_RB currently_RB used_VBN for_IN
        treatment_NN of_IN IBD_NNP ,_, the_DT literature_NN and_CC our_PRP$ data_NNS here_RB suggest_VBP
        that_IN NO_DT donors_NNS could_MD be_VB beneficial_JJ ._.
        An_DT improved_VBN understanding_NN of_IN the_DT interactions_NNS of_IN these_DT
        signals_NNS may_MD improve_VB our_PRP$ ability_NN to_TO understand_VB the_DT role_NN of_IN
        MAdCAM-_NNP 1_CD in_IN IBD_NNP and_CC design_VB effective_JJ therapies_NNS to_TO treat_VB
        it_PRP ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Abbreviations_NNP
        MAdCAM-_NNP 1_CD (_( mucosal_NN addressin_NN cell_NN adhesion_NN
        molecule-_NN 1_LS )_)
      
    
  
